옵션 체인은 다양한 행사가격과 만기일에 대한 Arbutus Biopharma의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Arbutus Biopharma에 대한 시장 심리를 평가합니다..

Arbutus Biopharma (NASDAQ:ABUS) 주식, 옵션 체인

Arbutus Biopharma

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Future Pandemics

Health Care

Legal

ABUS

MRNA

수요일 4월 3일, Arbutus Biopharma(NASDAQ:ABUS)의 주식은 회사가 법정에서 Moderna Inc(NASDAQ:MRNA)에 대한 소송을 제기할 권한을 부여받은 후 20% 이상 급등했다.



What Happened: Arbutus는 첫 소송에서 Moderna에 대해 클레임을 제기하는데 성공했는 데, 이 소송의 내용은 Moderna가 개발한 코로나 백신의 기반이 된

아르부투스 주식, 모더나와의 코로나 백신 특허 쟁송을 앞두고 급등

Arbutus Biopharma Corporation - Common Stock

Arbutus Biopharma Corp

WIIM

OKLO

Shares of nuclear stocks are trading higher following a Reuters report suggesting President Trump is planning executive orders to boost energy supply for AI.

Cantor Fitzgerald analyst Brett Knoblauch maintains HIVE Digital Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIVE#NASDAQ">HIVE</a>) with a Overweight and raises the price target from $5 to $5.5.

News

Price Target

Analyst Ratings

HIVE

Cantor Fitzgerald Maintains Overweight on HIVE Digital Technologies, Raises Price Target to $5.5

<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=3748747261&amp;u=https%3A%2F%2Fwww.neurocrine.com%2F&amp;a=Neurocrine+Biosciences%2C+Inc.">Neurocrine Biosciences, Inc.</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) today announced new patient-reported post-hoc data from the KINECT&#xAE;-HD study highlighting significant reductions in both cognitive and motor-related burdens among adults treated for Huntington's disease chorea with once-daily <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4457514-1&amp;h=1598651954&amp;u=https%3A%2F%2Fwww.ingrezza.com%2Fhuntingtons-chorea&amp;a=INGREZZA%C2%AE+(valbenazine)+capsules">INGREZZA&#xAE; (valbenazine) capsules</a>. KINECT-HD is the first and only clinical study to demonstrate measurable changes in cognitive and motor disease burden with a vesicular monoamine transporter 2 inhibitor (INGREZZA) in patients treated for chorea. These analyses will be presented at the 2025 Advanced Therapeutics in Movement &amp; Related Disorders Congress hosted by the Parkinson &amp; Movement Disorder Alliance in Washington, D.C.

NBIX

Neurocrine Reports Post-Hoc Data Demonstrating Cognitive, Motor Disease Burden With INGREZZA In HD Chorea

William Blair analyst Ryan Merkel initiates coverage on James Hardie Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) with a Outperform rating.

Initiation

William Blair Initiates Coverage On James Hardie Industries with Outperform Rating

Cantor Fitzgerald analyst Timur Ivannikov reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Overweight and maintains $8 price target.

Reiteration

PRQR

Cantor Fitzgerald Reiterates Overweight on ProQR Therapeutics, Maintains $8 Price Target

Major U.S. corporations are increasingly adding Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) to their balance sheets, raising concerns about potential market risks as the trend accelerates under <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46131815/trumps-crypto-advisor-david-sacks-says-july-will-be-a-big-month-says-president-supports-legislation-on-market-structure-and-stablecoins">President Donald Trump's administration</a>.
Companies like Trump Media &amp; Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) are driving this surge, recently announcing plans to invest around $2.5 billion in Bitcoin through stock and debt sales.
Trump's pro-crypto stance has significantly reshaped the regulatory landscape, Politico <a href="https://www.politico.com/news/2025/06/27/trump-bitcoin-treasury-wall-street-warren-00423673">reported</a>.
His administration's rollback of enforcement actions and push for crypto-friendly legislation have emboldened corporate America to embrace digital assets more aggressively. 
According to Standard Chartered, more than 60 publicly traded companies globally now hold over 673,000 Bitcoin, valued at approximately $75 billion as of May's end. 
Trump Media, among the most notable participants, is allocating substantial capital to Bitcoin, with CEO Devin Nunes calling it "an apex instrument of financial freedom."
Also Read: <a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46121954/retail-investors-can-now-trade-spacex-shares-heres-how">Retail Investors Can Now Trade SpaceX Shares: Here&#8217;s How</a>
Trump family members, including Eric Trump, have publicly championed Bitcoin adoption at recent industry events, reflecting a broader shift in sentiment where companies view Bitcoin as a viable treasury asset alongside traditional holdings like U.S. Treasuries.
Despite the enthusiasm, several lawmakers and experts are voicing caution. 
Senator Elizabeth Warren (D-Mass.) has warned that widespread corporate exposure to Bitcoin could amplify the economic fallout in the event of a future crypto crash, potentially leading to business failures and job losses across sectors.
Nic Carter, a partner at Castle Island Ventures, likened the current buildup of corporate Bitcoin holdings to &#8220;kindling&#8221; that could fuel a market collapse. 
Columbia University's Omid Malekan echoed the sentiment, pointing out the crypto industry's repeated cycles of overconfidence followed by painful corrections.
The practice, popularized by Michael Saylor's Strategy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>), has since been adopted by other firms like Japan's Metaplanet (OTC:<a class="ticker" href="https://www.benzinga.com/stock/MTPLF#OTC">MTPLF</a>) and the Trump-backed American Bitcoin.
These companies raise capital at low cost through stock and debt markets and use the proceeds to buy Bitcoin, a strategy that has driven their stock prices higher.
However, critics like investor Jim Chanos argue that these gains are unsustainable. 
He believes the valuations of such firms could plummet if Bitcoin prices fall, warning that many of these companies are not adding meaningful value beyond buying Bitcoin itself.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/crypto/cryptocurrency/25/06/46119440/why-did-this-uae-based-fund-just-purchase-100m-worth-of-trump-affiliated-wlfi-tokens">Why Did This UAE-Based Fund Just Purchase $100M Worth Of Trump-Affiliated WLFI Tokens?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Short Sellers

$BTC

MSTR

MTPLF

Corporate Bitcoin Buying Spree: Booming Strategy Or Ticking Financial Time Bomb?

BURU

NUBURU shares are trading higher after the company said the regulatory approval process for its acquisition of Tekne SpA is progressing 'positively and in line with expectations.'

LAES

WKEY

WISeKey's Subsidiary WISeSat.Space Is On Target To Deploy 100-Satellite Constellation By 2027 In Cooperation With WISekey And SEALSQ

Government

Regulations

NUBURU Says Regulatory Approval Process For Acquisition Of Tekne SpA Is 'progressing positively and in line with expectations'

Cantor Fitzgerald analyst Eric Schmidt reiterates Avidity Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNA#NASDAQ">RNA</a>) with a Overweight and maintains $96 price target.

Cantor Fitzgerald Reiterates Overweight on Avidity Biosciences, Maintains $96 Price Target

Stock Split

HSDT

Helius Medical Technologies Announces 1-For-50 Reverse Split Of Its Class A Common Stock

Offerings

OTRK

Ontrak Health Prices Public Offering Of 6,666,667 Shares And 26,666,668 Warrants At Combined Public Offering Price Of $0.60 Per Share And Accompanying Warrant; Gross Proceeds ~$4M

Omeros Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) today announced the recent submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA).
The MAA includes response-based analyses in narsoplimab-treated TA-TMA patients as well as analyses comparing overall survival between narsoplimab-treated patients and a well-matched external control group. Collectively, the results demonstrate a 61% response rate and, compared to the matched external control, a three-fold improvement in overall survival. The submission also includes outcomes in over 130 TA-TMA patients treated with narsoplimab under Omeros' expanded access program.
Narsoplimab has been granted orphan drug designation by the EMA for treatment in hematopoietic stem cell transplant, enabling review of the MAA through the centralized procedure. This allows for a single marketing authorization to cover all EU member states and the European Economic Area countries of Iceland, Liechtenstein and Norway.
The review procedure begins in mid-July and will follow a standard review timeline. The Committee for Medicinal Products for Human Use (CHMP) will conduct the scientific assessment and will issue an opinion at the end of the review. This opinion is typically adopted by the European Commission, with a final decision expected in mid-2026.
The MAA submission follows the acceptance for review by the U.S. Food and Drug Administration (FDA) of the resubmission of the Biologics License Application (BLA) for narsoplimab for the treatment of TA-TMA. The resubmission was assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025.

OMER

Omeros Submits MAA To EMA For Narsoplimab For Treatment Of Hematopoietic Stem Cell Transplant-Associated Thrombotic Microangiopathy

JMP Securities analyst Jonathan Wolleben reiterates ProQR Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) with a Market Outperform and maintains $8 price target.

JMP Securities Reiterates Market Outperform on ProQR Therapeutics, Maintains $8 Price Target

CISO

CISO Global Files Renewal Of S-3 Shelf Registration, Reducing Total Shelf From $300M To $100M

Macro Economic Events

Econ #s

Economics

US PCE Price index (YoY) (May) +2.3% vs +2.3% Est.

USA Core PCE Price Index (MoM) (May) +0.2% vs +0.1% Est.

PCE Price Index MoM For For May 0.1% Vs 0.1% Expected

Macro Notification

General

Core PCE Price Index (YoY) (May) +2.7% vs +2.6% Est.

JMP Securities analyst Patrick Walravens reiterates Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) with a Market Outperform and maintains $17 price target.

JMP Securities Reiterates Market Outperform on Sprinklr, Maintains $17 Price Target

Press Releases

Arbutus to Participate in H.C Wainwright @ Home Virtual Fireside Chat

Whitefort Capital Sends Letter to Arbutus Biopharma Board of Directors

Arbutus Provides 2025 Corporate and Financial Update

Management

Arbutus Announces Changes to Board of Directors and Appointment of Lindsay Androski as CEO

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Earnings

Arbutus Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Comments

Arbutus Biopharma

Arbutus Biopharma (ABUS) 옵션

Arbutus Biopharma (NASDAQ:ABUS) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌